Patrick Ohiani Moru
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Patrick Ohiani Moru has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Obiageli Eunice Nnodu
Department of Haematology and Blood Transfusion, University of Abuja, Abuja, Nigeria
3 shared publications - Ambroise Wonkam
McKusick-Nathans Institute and Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
2 shared publications Arthemon Nguweneza
SickleInAfrica Data Coordinating Centre(SADaCC) University of Cape Town, Cape Town, South Africa
2 shared publications- Abdulmalik Koya
Department of Cardiovascular Sciences, University of Leicester , Leicester LE3 9QP
1 shared publication - Agnes Jonathan
Department of Development Studies, School of Public Health and Social Sciences, Muhimbili University of Health and Allied Sciences, Dar es Salaam P.O. Box 65001, Tanzania
1 shared publication Akpaka A. Kalu
World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo
1 shared publication
Latest Publications
- Open Access
- 10 September 2026
- Published by Springer Nature in BMC Medical Ethics
Informed consent for somatic gene editing for sickle cell disease in sub-Saharan Africa: a scoping review
Somatic gene editing targets non-reproductive cells to treat genetic diseases like sickle cell disease (SCD) without affecting future generations. However, there are challenges in obtaining informed consent in sub-Saharan Africa (sSA) due to language barriers, cultural differences, and low health literacy. While promising, somatic gene editing carries risks such as off-target effects, unintended gene transfer, and potential activation of oncogenes. The aims of the review are to conduct an in-depth literature review of the current approaches to informed consent for somatic gene editing and gene therapy and identify potential areas for improvement, specifically in relation to SCD in sSA. Arksey and O’Malley five steps approach was adopted for this scoping review. A combined search via PubMed and EBSCOhost retrieved a total of 57 articles, Screening was conducted and a total of 23 articles were included in this review. Of the 23 articles 5 were original cross-sectional studies, 4 were reports, 10 were literature reviews, and 4 were opinion pieces, most of the articles were conducted in the USA (56.5%) and the least from Africa (4.3%). Themes included Patient Education, Risk Assessment, Paediatric Consideration, Ethical & Legal Consideration, Decision Making/Support, Privacy & Indemnification, Consenting process & Culture. In SSA, the consent process should use simple, clear language and visual aids for complex ideas, respect local customs and cultural norms and involve parents in decisions for children when appropriate. Privacy is a key concern, particularly due to stigmatization of genetic conditions like SCD. Informed consent is essential for gene therapy research in SCD in sSA. It is crucial to conduct a study to assess the level of gene therapy literacy among various stakeholders.
- 10 September 2026
- Published by Springer Nature in BMC Medical Ethics
Open AccessInformed consent for somatic gene editing for sickle cell disease in sub-Saharan Africa: a scoping review
Somatic gene editing targets non-reproductive cells to treat genetic diseases like sickle cell disease (SCD) without affecting future generations. However, there are challenges in obtaining informed consent in sub-Saharan Africa (sSA) due to language barriers, cultural differences, and low health literacy. While promising, somatic gene editing carries risks such as off-target effects, unintended gene transfer, and potential activation of oncogenes. The aims of the review are to conduct an in-depth literature review of the current approaches to informed consent for somatic gene editing and gene therapy and identify potential areas for improvement, specifically in relation to SCD in sSA. Arksey and O’Malley five steps approach was adopted for this scoping review. A combined search via PubMed and EBSCOhost retrieved a total of 57 articles, Screening was conducted and a total of 23 articles were included in this review. Of the 23 articles 5 were original cross-sectional studies, 4 were reports, 10 were literature reviews, and 4 were opinion pieces, most of the articles were conducted in the USA (56.5%) and the least from Africa (4.3%). Themes included Patient Education, Risk Assessment, Paediatric Consideration, Ethical & Legal Consideration, Decision Making/Support, Privacy & Indemnification, Consenting process & Culture. In SSA, the consent process should use simple, clear language and visual aids for complex ideas, respect local customs and cultural norms and involve parents in decisions for children when appropriate. Privacy is a key concern, particularly due to stigmatization of genetic conditions like SCD. Informed consent is essential for gene therapy research in SCD in sSA. It is crucial to conduct a study to assess the level of gene therapy literacy among various stakeholders.
- Open Access
- 4 March 2026
- Published by Taylor & Francis in Hemoglobin
- Vol. 50 (2) , 111-120
SickleInAfrica Consortium: A Seven-Country Study Evaluating the Performance of Dried Blood Spot Point-of-Care Testing in Newborn Screening for Sickle Cell Disease
Sickle cell disease (SCD) is caused by an inherited single-nucleotide substitution in both copies of the β-globin gene [HBB(Glu7Val)]. The sickle-cell mutation results in the production of an abnor...
- 4 March 2026
- Published by Taylor & Francis in Hemoglobin
- Vol. 50 (2) , 111-120
Open AccessSickleInAfrica Consortium: A Seven-Country Study Evaluating the Performance of Dried Blood Spot Point-of-Care Testing in Newborn Screening for Sickle Cell Disease
Sickle cell disease (SCD) is caused by an inherited single-nucleotide substitution in both copies of the β-globin gene [HBB(Glu7Val)]. The sickle-cell mutation results in the production of an abnor...
- Open Access
- 27 November 2023
- Published by Springer Nature in Gene Therapy
- Vol. 31 (5-6) , 202-208
Looking ahead: ethical and social challenges of somatic gene therapy for sickle cell disease in Africa
Somatic gene therapy will be one of the most exciting practices of genetic medicine in Africa and is primed to offer a “new life” for persons living with sickle cell disease (SCD). Recently, successful gene therapy trials for SCD in the USA have sparked a ray of hope within the SCD community in Africa. However, the high cost, estimated to exceed 1.5 million USD, continues to be a major concern for many stakeholders. While affordability is a key global health equity consideration, it is equally important to reflect on other ethical, legal and social issues (ELSIs) that may impact the responsible implementation of gene therapy for SCD in Africa. These include informed consent comprehension, risk of therapeutic misestimation and optimistic bias; priorities for SCD therapy trials; dearth of ethical and regulatory oversight for gene therapy in many African countries; identifying a favourable risk-benefit ratio; criteria for the selection of trial participants; decisional conflict in consent; standards of care; bounded justice; and genetic tourism. Given these ELSIs, we suggest that researchers, pharma, funders, global health agencies, ethics committees, science councils and SCD patient support/advocacy groups should work together to co-develop: (1) patient-centric governance for gene therapy in Africa, (2) public engagement and education materials, and (3) decision making toolkits for trial participants. It is also critical to establish harmonised ethical and regulatory frameworks for gene therapy in Africa, and for global health agencies to accelerate access to basic care for SCD in Africa, while simultaneously strengthening capacity for gene therapy.
- 27 November 2023
- Published by Springer Nature in Gene Therapy
- Vol. 31 (5-6) , 202-208
Open AccessLooking ahead: ethical and social challenges of somatic gene therapy for sickle cell disease in Africa
Somatic gene therapy will be one of the most exciting practices of genetic medicine in Africa and is primed to offer a “new life” for persons living with sickle cell disease (SCD). Recently, successful gene therapy trials for SCD in the USA have sparked a ray of hope within the SCD community in Africa. However, the high cost, estimated to exceed 1.5 million USD, continues to be a major concern for many stakeholders. While affordability is a key global health equity consideration, it is equally important to reflect on other ethical, legal and social issues (ELSIs) that may impact the responsible implementation of gene therapy for SCD in Africa. These include informed consent comprehension, risk of therapeutic misestimation and optimistic bias; priorities for SCD therapy trials; dearth of ethical and regulatory oversight for gene therapy in many African countries; identifying a favourable risk-benefit ratio; criteria for the selection of trial participants; decisional conflict in consent; standards of care; bounded justice; and genetic tourism. Given these ELSIs, we suggest that researchers, pharma, funders, global health agencies, ethics committees, science councils and SCD patient support/advocacy groups should work together to co-develop: (1) patient-centric governance for gene therapy in Africa, (2) public engagement and education materials, and (3) decision making toolkits for trial participants. It is also critical to establish harmonised ethical and regulatory frameworks for gene therapy in Africa, and for global health agencies to accelerate access to basic care for SCD in Africa, while simultaneously strengthening capacity for gene therapy.